zurück
zur Veranstaltungsübersicht
WHO-Workshop:
Models of Medication supported Treatment for Opioid Addicts
Sportschloss Velen, Germany,
25-27 April 2002
Workshop organized jointly by
WHO and Federal Ministry of Health of Germany
Local organizing agency: DLR, Projektträger
Gesundheitsforschung, Bonn
Download of the
Report "Models of Medication Supported Treatment for
Opioid Addicts"
Programme
Thursday 25
Opening of the workshop
and welcome
K.-T. Schröder,
State-Secretary, Federal Ministry of Health of Germany
C. Prüfer-Storcks, State-Secretary, Ministry of Health of
North Rhine-Westphalia
H. Nikogosian, Head, Noncommunicable Diseases and Mental
Health, WHO
Session 1: Heroin-assisted
treatment for opioid addicts (Chair: K. Mann, Mannheim,
Germany)
J.
Rehm (Zurich, Switzerland): Evaluation of the Swiss trial
W. van den Brink (Amsterdam,
The Netherlands): Results of the Dutch trial (see www.ccbh.nl)
M. Krausz (Hamburg, Germany):
Concept and status quo of the German trial
M. Casas (Barcelona, Spain):
Concept and conditions of the oral heroin trial in Barcelona
(Catalunya,
Spain)
B. Fischer (Toronto, Canada):
Overview on developments in different countries with special
emphasis on the North American situation
General discussion
Friday 26
Session 2: Developments in
medication-assisted withdrawal and pharmacotherapy (Chair: M.
Krausz, Hamburg, Germany)
J. Wolfgramm (Tübingen,
Germany): Extinction of addiction memory (I)
G. Mundle (Hornberg,
Germany): Extinction of addiction memory (II)
R. Spanagel (Mannheim,
Germany): New pharmacotherapies
F. Tretter (München,
Germany): Withdrawal under anaesthesia
Session 3: Differential
practice of medication-assisted substitution treatment for
opioid addicts (Chair: J. Rehm, Zurich, Switzerland)
E. Buning (Amsterdam, The
Netherlands): Activities of the Euronetwork Methadone
G. Fischer (Vienna, Austria):
Buprenorphine and slow-release morphine in the treatment of
opioid dependence
U.
Verthein (Hamburg, Germany): German experience with
medication-assisted substitution treatment
G.
Woody (Philadelphia, USA): Methadone treatment in the USA
L. Sakoman (Zagreb, Croatia):
The experience with methadone maintance programmes in Croatia
J. Strang (London, UK):
Injectable methadone prescribing in the UK: rationale, extent
of the practice, and the lack of scientific study
M. Auriacombe (Bordeaux,
France): Buprenorphine based treatment
A.
Elkashef (NIDA, USA): The development of buprenorphine for the
treatment of opiate addiction in the USA
Saturday 27
Session 4: Psychosocial
interventions and their significance for treatment (Chair:
C. Zenker, Münster, Germany)
R. Basdekis-Josza (Hamburg,
Germany): Psychoeducation in the German heroin trial
I.
Vogt (Frankfurt, Germany): Case-Management / Motivational
Interviewing in the German heroin trial
G. Bühringer (München,
Germany); Impact of payments on patient compliance
G.
Woody (Philadelphia, USA): Psychosocial treatments for cocaine
dependents
Concluding remarks and
farewell
J. Rehm, Zurich, Switzerland
M. Köhler, German Ministry of Health, Bonn
P. Lazarov, WHO Regional Office Europe, Kopenhagen
zurück
zur Veranstaltungsübersicht |